MEDNAX, Inc.’s MD third-quarter 2019 adjusted earnings of 91 cents per share came in line with the Zacks Consensus Estimate. Meanwhile, the bottom line declined 3.2% % year over year due to high expenses.
Quarterly Details
The company generated revenues of $889 million, surpassing the Zacks Consensus Estimate by 1.8%. However, the top line dipped 0.9% from the year-ago period.
Same-unit revenues inched up 4.2% year over year, mainly driven by higher patient volume.
General and administrative expenses rose 6.9% to $102.4 million due to higher legal, information technology and revenue cycle costs.
Interest expense of the company escalated 37.2% to $29.9 million for the third quarter, primarily due to higher effective interest rate on borrowings between two periods.
In the quarter under review, Adjusted EBITDA totaled $133 million, up 2.3% year over year.
Mednax, Inc Price, Consensus and EPS Surprise
Mednax, Inc price-consensus-eps-surprise-chart | Mednax, Inc Quote
Financial Update
As of Sep 30, 2019, the company had cash and cash equivalents of about $28.9 million, down 36.5% from the level at 2018 end.
The company incurred total debt of $1.9 billion, down 1.8% from the level at 2018 end and total assets of $4.2 billion, down 27.7% from the level at 2018 end.
Cash flows from operating activities were $155.9 million, up 15.3% year over year.
Fourth-Quarter Outlook
For the fourth quarter of 2019, the company expects adjusted EPS in the band of 87-95 cents.
This guidance assumes that total same-unit revenue growth for the three months ended Dec 31, 2019 will be in a 1-3% range from the prior-year period. It also assumes that the effective tax rate for the fourth quarter is 26.5%.
Shares outstanding are predicted to be around 83.4 million.
Adjusted EBITDA from continuing operations is expected between $125 million and $135 million.
2019 Guidance
Based on its third-quarter results, the company now expects Adjusted EBITDA for the full year to be around $500 million.
Zacks Rank
MEDNAX carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Players
Among other players from the medical sector, having already reported third-quarter earnings, the bottom-line results of UnitedHealth Group Incorporated UNH, Anthem Inc. ANTM and Centene Corporation CNC topped the respective Zacks Consensus Estimate.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment